GIPR and obesity due to melanocortin 4 receptor deficiency: Similarly, pharmacologically targeting the GIPR has yielded conflicting results as, paradoxically, both GIPR agonists and GIPR antagonists produce weight loss in preclinical models of obesity [2,[4], [5], [6], [7]].